Funding supports Sorrento's staph infection work

Sorrento Therapeutics a two-year, $600,000 grant from the National Institute of Allergy and Infectious Diseases to support the company's develoment of antibody therapeutics and vaccines for Staph infections. The grant will help fund Phase I studies and could eventually lead to funding for Phase II trials. Article

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.